• CEO & Co-founder:
    Dr. Anand Anandkumar
  • Co-founders:
    Dr. Santanu Datta, Dr. V Balasubramanian, Dr. Shahul Hameed



Development of Novel Class of Antibiotics exhibiting Broad Spectrum Activity against all-known classes of drug resistant bacteria.

Superbugs - microorganisms resistant to antibiotics - cause life-treating illness. By 2050, drug-resistant infections are projected to kill ~10 million people per year. Bugworks aims to tackle this global Anti-microbial Resistance (AMR) crisis by developing a novel class of antibiotics exhibiting broad spectrum activity against Gram-negative and Gram-positive infections. Using proprietary ELUDE™ platform, Bugworks has come up with a first-in-class antibiotic series that is effective on all known classes of drug resistant bacteria. In July 2017, Bugworks became the first Asian company to win the prestigious Carb-X grant.



Bugworks core team has its roots in AstraZeneca India. The Bugworks Research lab in Bangalore, India has a team of several scientists with PhDs in the fields of Biotechnology, Medicinal Chemistry, Microbiology and Pharmaceutical Sciences with a combined experience of over 200 years.


Efflux Unbinding – Bugworks compound can achieve efflux avoidance while maintaining anti-bacterial effect
Dual-target Mechanism - Bugworks compound attacks two enzymes relating to bacterial DNA structure- Gyrase and Typo IV - with equal potency
Broad-spectrum utility - Effective on all known classes of drug resistant bacteria (NDM, KPC, ESBL, MRSA etc.)

UTEC value up

UTEC is helping Bugworks to explore partnerships with several Japanese pharma corporations. Also, UTEC is fostering the collaboration between Bugworks and Prof. Satoshi Murakami of Tokyo Institute of Technology. Prof. Murakami, who discovered the crystal structure of bacterial multidrug efflux transporter AcrB, has joined Bugworks technical board as scientific advisor.
  • Proprietary ELUDE™ platform of Bugworks